

IHCP *bulletin*

INDIANA HEALTH COVERAGE PROGRAMS BT202544 APRIL 1, 2025

Pharmacy updates approved by the Office of Medicaid Policy and Planning March 2025

The Indiana Health Coverage Programs (IHCP) announces updates to the prior authorization (PA) criteria, Statewide Uniform Preferred Drug List (SUPDL) and Preferred Brand Drug List as approved *ad interim* by the Office of Medicaid Policy and Planning (OMPP) until the next meeting of the Drug Utilization Review (DUR) Board.

PA changes

Changes to PA criteria for MASH/MASLD Agents and Non-SUPDL Agents PA and Step Therapy will be effective for PA requests submitted on or after May 1, 2025. PA criteria for MASH/MASLD Agents and Non-SUPDL Agents PA and Step Therapy apply to the fee-for-service (FFS) benefit only. The PA criteria are posted on the *Pharmacy Prior Authorization Criteria and Forms* page on the Optum Rx Indiana Medicaid website, accessible from the [Pharmacy Services](#) page at in.gov/medicaid/providers.



Changes to the SUPDL

Changes to the SUPDL will be effective for FFS claims with dates of service (DOS) on or after May 1, 2025, and managed care claims with DOS on or after May 15, 2025. See Table 1 for a summary of SUPDL changes.

Table 1 – SUPDL changes, effective for FFS DOS on or after May 1, 2025, and managed care DOS on or after May 15, 2025

Drug class	Drug	SUPDL status
Direct Oral Anticoagulants	rivaroxaban	Nonpreferred

Changes to the Preferred Brand Drug List

Changes to the Preferred Brand Drug List will be effective for FFS claims with DOS on or after May 1, 2025, and managed care claims with DOS on or after May 15, 2025. See Table 2 for a summary of Preferred Brand Drug List changes.

Table 2 – Updates to Preferred Brand Drug List, effective for FFS DOS on or after May 1, 2025, and managed care DOS on or after May 15, 2025

Name of medication	Preferred Brand Drug List status
Xarelto (rivaroxaban) 2.5 mg tablet*	Add to Preferred Brand Drug List
Bromsite (bromfenac) 0.075% solution	Remove from Preferred Brand Drug List

**As additional strengths of Xarelto are released, they will be programmed as Brand Preferred.*

For more information

The PA criteria, SUPDL and Preferred Brand Drug List can be found on the [Optum Rx Indiana Medicaid website](#). Notices of the DUR Board meetings and agendas are posted on the [Indiana Family and Social Services Administration \(FSSA\) website](#) at in.gov/fssa. Click **FSSA Calendar** on the left side of the page to access the events calendar.

Please direct FFS pharmacy PA requests and questions about the SUPDL under the FFS pharmacy benefit or about this bulletin to the Optum Rx Clinical and Technical Help Desk by calling toll-free 855-577-6317.

Individual managed care entities (MCEs) establish and publish PA criteria within the managed care delivery system. Questions about managed care PA should be directed to the MCE with which the member is enrolled.

COPIES OF THIS PUBLICATION

If you need additional copies of this publication, please download them from the [IHCP Bulletins](#) page of the IHCP provider website at in.gov/medicaid/providers.

SIGN UP FOR IHCP EMAIL NOTIFICATIONS

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope or sign up from the [IHCP provider website](#) at in.gov/medicaid/providers.

